Novartis' Tasigna gets treatment-free remission FDA label expansion

FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some chronic myelogenous leukemia (CML) patients

Read the full 213 word article

User Sign In